Posted on

PsyBio Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones

PsyBio Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones

OXFORD, Ohio and COCONUT CREEK, Fla., Nov. 30, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (” PsyBio ” or the ” Company “), an intellectual property driven biotechnology company focusing on discovering and developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that it has reported its unaudited financial results for the interim period ended September 30, 2021 and provided shareholders with a corporate update.

PSYBIO THERAPEUTICS logo (CNW Group/PsyBio Therapeutics Corp.)

Third Quarter 2021 Financial Results

A copy of the unaudited condensed consolidated interim financial statements prepared in accordance with International Financial Reporting Standards and the corresponding management’s discussion and analysis for the interim period ended September 30, 2021, can be found under PsyBio’s profile at www.sedar.com .

Intellectual Property and Clinical Development Milestones

  • The Company furthered its intellectual property portfolio by filing six additional manufacturing patent applications with the United States Patent and Trademark Office (the ” USPTO “) that cover a broad range of approaches to PsyBio’s biologic methodology as it pertains to the current landscape of biotechnology.
  • The Company successfully demonstrated the ability to manufacture PsyBio-11040, one of its first promising therapeutic candidates, at commercial scale.
  • The Company submitted a pre-Investigational New Drug (” IND “) Application request to the United States Food and Drug Administration (” FDA “) seeking guidance on data necessary to warrant an IND submission.
  • The Company filed a provisional patent application with the USPTO entitled Psilocybin and Norbaeocystin Compositions and Methods of Treatment, which contained 67 new inventive claims.
  • The Company filed a provisional patent application with the USPTO entitled NMDA Receptor Antagonist-Containing Compositions and Methods of Treatment and initiated a new program to study N-methyl-D-aspartate (” NMDA “) receptor antagonists and associated analogs for potential activity against a variety of human health conditions.

Corporate Finance Update

  • The Company filed and obtained receipts for a final base shelf prospectus dated October 28, 2021, which is expected to help facilitate institutional investor access to the Company’s securities.
  • The Company’s subordinate voting shares were made eligible for electronic clearing and settlement through the Depository Trust Company (” DTC “) in the United States , which is anticipated to benefit investors with increased liquidity and execution speed.
  • The Company was included in AdvisorShares Psychedelics Exchange Traded Fund, which is listed on the NYSE Arca under the ticker symbol (NYSE: PSIL) and was formed to actively manage investments in the emerging psychedelic drugs sector.
    The Company’s subordinate voting shares commenced trading on the OTCQB Venture Market at market open on July 14, 2021 under the symbol “PSYBF”.
  • The Company purchased an aggregate of 397,500 subordinate voting shares under its normal course issuer bid (” NCIB “) during the month of October 2021 , at an average price of $0.314 per share. All shares purchased under the NCIB were cancelled.

About PsyBio Therapeutics Corp.

PsyBio is an intellectual property driven biotechnology company focusing on discovering and developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (” forward-looking information “) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward looking-statements in this press release include statements regarding: the ability of PsyBio to develop novel formulations to potentially treat neurologic and psychologic conditions and other disorders; the ability of PsyBio to launch clinical trials; the ability of PsyBio to build its intellectual property portfolio of novel drug candidates; the ability of PsyBio to move target candidates into scaled commercial manufacturing and regulatory application; the ability to achieve cost competitive synthesis with reduced environmental impact over current production methods; the ability of PsyBio to move target candidates into scaled commercial manufacturing and regulatory application; the impact of DTC eligibility on existing and prospective investors’ ability to trade the Company’s subordinate voting shares; and the impact of DTC eligibility on the liquidity of the Company’s subordinate voting shares.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: PsyBio will be successful in protecting its intellectual property; PsyBio will be successful in discovering new valuable target molecules; PsyBio will file its initial pre-IND Application request and IND Application within anticipated timeframes; PsyBio will be successful in obtaining IND Applications and will be able to obtain all necessary approvals for clinical trials; PsyBio will be successful in launching clinical trials; the results of preclinical safety and efficacy testing will be favourable; PsyBio’s technology will be safe and effective; a confirmed signal will be identified in PsyBio’s selected indications; and that drug development involves long lead times, is very expensive and involves many variables of uncertainty. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio’s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The FDA or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (the ” TSXV “) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2021/30/c7717.html

Posted on

PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications

PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications

OXFORD, Ohio and COCONUT CREEK, Fla. , Nov. 19, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (” PsyBio ” or the ” Company “), an intellectual property driven biotechnology company developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that it has filed six additional provisional manufacturing patent applications to further expand its intellectual property portfolio.

“These patent filings are critical components of PsyBio’s corporate development strategy. Continuing to add intellectual property protection provides us with certainty when developing technology for the exclusive use of our team as we continue to develop proprietary bacterial strains,” stated Michael Spigarelli , MD, PhD, MBA, PsyBio’s Chief Medical Officer. “These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

These new manufacturing patents cover a broad range of approaches to PsyBio’s biologic methodology as it pertains to the current landscape of biotechnology.  PsyBio remains interested in developing the intellectual property landscape within the psycho-targeted development drug arena.

“Adding these new patent applications to our existing intellectual property portfolio demonstrates PsyBio’s commitment to being a leader in developing psycho-targeted therapeutic candidates,” stated Evan Levine , PsyBio’s Chief Executive Officer. “Our approach is to treat IP as a critical part of effectively designing and developing therapeutics to potentially treat specific clinical conditions. Submitting those to the appropriate agencies for approval and regulatory authorization to uphold our commitment to help improve mental and neurological health.”

About PsyBio Therapeutics Corp.

PsyBio Therapeutics is an intellectual property driven biotechnology company developing new, bespoke, fully approved, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (” forward-looking information “) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward looking-statements in this press release include statements regarding: the ability of PsyBio to develop novel formulations to potentially treat neurologic and psychologic conditions and other disorders; the ability of PsyBio to launch clinical trials; the ability of PsyBio to build and protect its intellectual property portfolio of novel drug candidates; the ability of PsyBio to move target candidates into scaled commercial manufacturing and regulatory application; the ability to achieve cost competitive synthesis with reduced environmental impact over current production methods; and the ability of PsyBio to move target candidates into scaled commercial manufacturing and regulatory application.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: PsyBio will be successful in protecting its intellectual property; PsyBio will be successful in discovering new valuable target molecules; PsyBio will file one or more IND Applications with the FDA; PsyBio will be successful in obtaining all necessary approvals for clinical trials; PsyBio will be successful in launching clinical trials; the results of preclinical safety and efficacy testing will be favourable; PsyBio’s technology will be safe and effective; a confirmed signal will be identified in PsyBio’s selected indications; and that drug development involves long lead times, is very expensive and involves many variables of uncertainty. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio’s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The United States Food and Drug Administration (” FDA “) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (the ” TSXV “) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

 

Cision View original content: http://www.newswire.ca/en/releases/archive/November2021/19/c9615.html

Posted on

Psybio Announces Filing of Final Base Shelf Prospectus

Psybio Announces Filing of Final Base Shelf Prospectus

OXFORD, Ohio and COCONUT CREEK, Fla. , Nov. 1, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTC: PSYBF) (” PsyBio ” or the ” Company “), announced today that it has filed and obtained receipts for a final base shelf prospectus. The final base shelf prospectus dated October 28, 2021 was filed with the securities regulatory authorities in each of the provinces and territories of Canada .

The final base shelf prospectus is valid for a 25-month period, during which time PsyBio may offer and issue, from time to time, subordinate voting shares, multiple voting shares, warrants, options, subscription receipts, debt securities and units, or any combination thereof, having an aggregate offering price of up to C$100,000,000 . The specific terms of any offering of securities will be contained in a shelf prospectus supplement filed at the time of such offering.

“The shelf filing is another step that the Company is taking to offer institutional investors streamlined access to invest in the Company’s securities,” said Evan Levine , Chief Executive Officer of the Company.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States or in any jurisdiction where the offer, sale or solicitation would be unlawful. The securities referred to in this press release may not be offered or sold in the United States absent registration or an applicable exemption from registration.

The Company also announces that, effective November 2, 2021 , it has retained Integral Wealth Securities Limited (” Integral “) to provide market making services in accordance with the policies of the TSX Venture Exchange (the ” TSXV “), for the purposes of maintaining an orderly market and improving the liquidity of the Company’s subordinate voting shares traded on the TSXV.

In consideration of the services provided by Integral, the Company will pay Integral a monthly cash fee of C$7,500, plus any reasonable costs and expenses it incurs in connection with the services provided. The Company has retained Integral for no less than a three-month term. Integral will not receive any securities of PsyBio as compensation pursuant to the agreement. The Company and Integral are unrelated and unaffiliated entities. Integral does not currently own any securities of PsyBio. However, Integral and its clients may acquire a direct interest in the securities of the Company. Effective as of the close of business on November 1, 2021 , Generation IACP Inc. will cease providing market making services to the Company.

About PsyBio Therapeutics Corp.

PsyBio is an intellectual property driven biotechnology company developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain statements that constitute “forward-looking information” (” forward-looking information “) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.

In disclosing forward-looking information, the Company has made certain assumptions, including that the retention of Integral will help maintain an orderly market and improve the liquidity of the Company’s subordinate voting shares. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The United States Food and Drug Administration (” FDA “) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSXV has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

Cision View original content: http://www.newswire.ca/en/releases/archive/November2021/01/c7979.html

Posted on

PsyBio Therapeutics CEO, Evan Levine, to Participate in Panel Discussion at the MedTech Innovation Conference on October 29th

PsyBio Therapeutics CEO, Evan Levine, to Participate in Panel Discussion at the MedTech Innovation Conference on October 29th

OXFORD, Ohio and COCONUT CREEK, Fla., Oct. 25, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company developing novel, bespoke, approvable, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that Evan Levine, CEO and Chairman, has been invited to participate in a panel discussion at the MedTech Innovation Conference to be held at the AV Irvine in Irvine, California on October 28-29, 2021.

Panel Details:
‘Innovation in Mental Health’
Thursday, October 29th at 10:40 am PT / 1:40 pm ET
Registration: here

For more information on the conference, or to schedule a one-on-one meeting with the PsyBio management team, please contact KCSA Strategic Communications at PsyBio@kcsa.com.

About PsyBio Therapeutics Corp.

PsyBio Therapeutics is an intellectual property driven biotechnology company developing novel, bespoke, approvable, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a Bio Medicinal Chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring, specifically because they are already known to have an effect within the brain.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The U.S. Food and Drug Administration (“FDA“) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA- approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (“TSXV“) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

For further information: Evan Levine, CEO, PsyBio Therapeutics Corp., t: 513.449.9585, e: ir@psybiolife.com; Investor Enquiries: Valter Pinto or Tim Regan, KCSA Strategic Communications, t: 212.896.1254, e: valter@kcsa.com

Posted on

PsyBio Therapeutics Announces Electronic Clearing and Settlement by Depository Trust Company

PsyBio Therapeutics Announces Electronic Clearing and Settlement by Depository Trust Company

OXFORD, Ohio and COCONUT CREEK, Fla., Oct. 21, 2021 /CNW/ — PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company developing new, bespoke, approvable psycho-targeted therapeutics to potentially improve mental and neurological health, is pleased to announce that its subordinate voting shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC“) in the United States.

“With DTC eligibility, existing investors may benefit from greater liquidity and execution speeds. This also opens the door to new investors that may have been previously restricted from trading in our subordinate voting shares and simplifies the process of trading our subordinate voting shares in the United States,” stated Evan Levine, CEO of PsyBio. “The ancitipated liquidity increase is expect to provide current and prospective US investors further opportunities to participate in PsyBio’s growth. This is a timely development, as PsyBio recently announced that it has submitted its first Pre-Investigational New Drug (“IND“) Application Meeting request to the US Food and Drug Administration and successfully demonstrated commercial scale manufacturing feasibility.”

DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly-traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered to be DTC eligible. DTC eligibility is expected to create a seamless electronic trading process and thereby enhance the liquidity of the Company’s subordinate voting shares.

About PsyBio Therapeutics Corp.
PsyBio Therapeutics is an intellectual property driven biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the potential treatment of mental health challenges and other disorders. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company is also researching and developing new non-naturally occurring molecular structures which may have unique therapeutics properties.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute “forward-looking information” (“forward-looking information“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this press release include statements regarding: the ability of PsyBio to develop novel formulations to potentially improve mental and neurological health, treat mental health challenges and other disorders; the impact of DTC eligibility on existing and prospective investors’ ability to trade the Company’s subordinate voting shares; and the impact of DTC eligibility on the liquidity of the Company’s subordinate voting shares.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: DTC eligibility will improve the electronic trading process and thereby enhance the liquidity of the Company’s subordinate voting shares; PsyBio will be successful in discovering new valuable target molecules; PsyBio will be successful in obtaining IND Applications and will be able to obtain all necessary approvals for clinical trials; PsyBio’s technology will be safe and effective; and that drug development involves long lead times, is very expensive and involves many variables of uncertainty. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio’s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The United States Food and Drug Administration (“FDA“) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (the “TSXV“) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

For further information: For further information contact: Evan Levine, CEO, PsyBio Therapeutics Corp., t: 513.449.9585, e: ir@psybiolife.com, Investor Enquiries: Valter Pinto / Tim Regan, KCSA Strategic Communications, t: 212.896.1254, e: valter@kcsa.com , 46286566.3, https://www.psybiolife.com/

Posted on

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

NEW YORK, Oct. 18, 2021 /PRNewswire/ — Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

REGISTER OR LOGIN NOW AT: https://bit.ly/3acCV7Y

The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “virtual trade booth”.

Presentations

PresentationTicker(s)
Fireside Chat – Amy Emerson, CEO of MAPS Public Benefit Corporation
“Investing in Psychedelics and CNS Treatments”       Lindsay Hoover, Partner, JLS Fund       Dan Ahrens, PM of the Psychedelics ETF (NYSEArca: PSIL), AdvisorShares Investments       Tim Regan, SVP, KCSA Strategic Communications
Small Pharma Inc.(Pink: DMTTF | TSX-V: DMT)
Awakn Life Sciences Corp.(OTCQB: AWKNF | NEO: AWKN)
HMNC Brain Health(Private Company)
Enveric Biosciences(NASDAQ: ENVB)
Mind Cure Health Inc.(OTCQX: MCURF | CSE: MCUR)
Field Trip Health Ltd.(NASDAQ: FTRB | TSX: FTRP)
Novamind Inc.(OTCQB: NVMDF | CSE: NM)
BetterLife Pharma Inc.(OTCQB: BETRF | CSE: BETR)
MYND Life Sciences Inc.(Pink: MYNDF | CSE: MYND)
FSD Pharma Inc.(NASDAQ: HUGE | CSE: HUGE)
Mindset Pharma Inc.(OTCQB: MSSTF | CSE: MSET)
PsyBio Therapeutics Corp.(OTCQB: PSYBF | TSX-V: PSYB)
Psyched Wellness Ltd.(OTCQB: PSYCF | CSE: PSYC)
Bright Minds Biosciences Inc.(OTCQB: BMBIF | CSE: DRUG)
Cybin Inc.(NYSE American: CYBN | NEO: CYBN)
Mydecine Innovations Group(Pink: MYCOF | NEO: MYCO)
NeonMind Biosciences Inc.(OTCQB: NMDBF | CSE: NEON)
Numinus Wellness Inc.(TSX-V: NUMI)
Tryp Therapeutics Inc.(OTCQB: TRYPF | CSE: TRYP)
Wesana Health Holdings Inc.(OTCQB: WSNAF | CSE: WESA)
Filament Health Corp.(OTCQB: FLHLF | NEO: FH)

To facilitate investor relations scheduling, please contact KCSA Strategic Communications a conference@kcsa.com.

About Virtual Investor ConferencesSM
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

To learn more about VIC and view a complete calendar of events, please visit www.virtualinvestorconferences.com.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

SOURCE VirtualInvestorConferences.com

Posted on

PsyBio Therapeutics to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th

PsyBio Therapeutics to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th

OXFORD, Ohio and COCONUT CREEK, Fla., Oct. 11, 2021 /PRNewswire/ — PsyBio Therapeutics Corp. (TSXV: PSYB, OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company developing novel, bespoke, approvable, psycho-targeted therapeutics to improve mental and neurological health, today announced that Evan Levine, CEO and Chairman of PsyBio, will present at the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on Thursday, October 14th at 10:30 a.m. ET.

(PRNewsfoto/VirtualInvestorConferences.com)

To attend the conference, please register here.

For more information on the conference, or to schedule a one-on-one meeting with the PsyBio management team, please contact KCSA Strategic Communications at PsyBio@kcsa.com.

About PsyBio Therapeutics Corp.
PsyBio Therapeutics is an intellectual property driven biotechnology company developing novel, bespoke, approvable, psycho-targeted therapeutics to improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a Bio Medicinal Chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring, specifically because they are already known to have an effect within the brain.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/psybio-therapeutics-to-present-at-the-kcsa-psychedelics-virtual-investor-conference-on-october-14th-301396206.html

SOURCE VirtualInvestorConferences.com

Posted on

PsyBio Therapeutics Successfully Demonstrates Commercial Scale Manufacturing Feasibility

PsyBio Therapeutics Successfully Demonstrates Commercial Scale Manufacturing Feasibility

PsyBio is one of the only biotechnology companies in the psychedelic industry with the ability to manufacture therapeutics at commercial scale

OXFORD, Ohio and COCONUT CREEK, Fla., Oct. 7, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company developing new, bespoke, approvable psycho-targeted therapeutics to potentially improve mental and neurological health, today reported that it has demonstrated the ability to manufacture PsyBio-11040, one of its first promising therapeutic candidates, at commercial scale. This achievement is the result of numerous dedicated employees, consultants and contractors of PsyBio committing thousands of hours and almost a year of efforts that have taken the technology, exclusively licensed to PsyBio, from bench scale to commercial scale.

“This achievement demonstrates the formal utility of the technology to produce psycho-targeted therapeutic candidates,” stated Evan Levine, PsyBio’s Chief Executive Officer. “This is the culmination of efforts across the Company and provides a basis for our confidence moving forward with candidate development as one of the only biotechnology companies in the psychoactive therapeutic industry with the ability to manufacture therapeutics at scale.”

Scale up to full production was achieved utilizing a commercially available, stainless-steel bioreactor with integrated continuous read out probes as well as ongoing sample analysis to gather real time data on the process. Similar pilot scale processes were tested, and modifications were made as necessary to provide the information on which the larger scale processes were based. It is expected that similar scale up procedures and outcomes will be replicated across PsyBio’s therapeutic candidate strains as additional promising target candidates undergo tech transfer to commercial manufacturing. The Company expects to commence manufacturing on a commercial scale in the first quarter of 2022.

“This demonstration is very helpful as it provides the ability to manufacture a sufficient quantity of product to allow further development including producing clinical batches for preliminary stability testing and pre-clinical/clinical testing from a single production batch,” stated Michael Spigarelli, MD, PhD, MBA, PsyBio’s Chief Medical Officer. “This will allow us to move forward with the Chemistry Manufacturing and Controls (CMC) development processes as part of PsyBio’s Quality by Design (QbD) strategy to produce psycho-targeted therapeutics intended to improve mental and neurological health.”

About PsyBio Therapeutics Corp.

PsyBio Therapeutics is an intellectual property driven biotechnology company developing new, bespoke, approvable psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward looking-statements in this press release include statements regarding: the ability of PsyBio to move target candidates into scaled commercial manufacturing and regulatory application; the ability of PsyBio to commence manufacturing on a commercial scale within anticipated timeframes; the ability of PsyBio to develop novel formulations to potentially treat neurologic and psychologic conditions and other disorders; the ability of PsyBio to launch clinical trials; the ability of PsyBio to build its intellectual property portfolio of novel drug candidates; and the ability to achieve cost competitive synthesis with reduced environmental impact over current production methods.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: PsyBio will be successful in protecting its intellectual property; PsyBio will be successful in discovering new valuable target molecules; PsyBio will be successful in obtaining Investigational New Drug Applications and will be able to obtain all necessary approvals for clinical trials; PsyBio will be successful in launching clinical trials; the results of preclinical safety and efficacy testing will be favourable; PsyBio’s technology will be safe and effective; a confirmed signal will be identified in PsyBio’s selected indications; and that drug development involves long lead times, is very expensive and involves many variables of uncertainty. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio’s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The United States Food and Drug Administration (“FDA“) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (the “TSXV“) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

For further information: Evan Levine, CEO, PsyBio Therapeutics Corp., t: 513.449.9585, e: ir@psybiolife.com; Investor Enquiries: Valter Pinto or Tim Regan, KCSA Strategic Communications, t: 212.896.1254, e: valter@kcsa.com

Posted on

PsyBio Therapeutics Announces Pre-IND Application Request Has Been Submitted to the United States Food and Drug Administration

PsyBio Therapeutics Announces Pre-IND Application Request Has Been Submitted to the United States Food and Drug Administration

OXFORD, Ohio and COCONUT CREEK, Fla., Sept. 23, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company developing novel, bespoke, fully approved, psycho-targeted therapeutics to potentially improve mental and neurological health, today reported it has submitted its first pre-Investigational New Drug (“IND“) application meeting request to the United States Food and Drug Administration (“FDA“) as part of the regulatory submission process.

The FDA’s Pre-Investigational New Drug Application (IND) Consultation Program fosters early communications between sponsors and new drug review divisions to provide guidance on the data necessary to warrant IND submission.[1] PsyBio is dedicated to working towards obtaining all necessary regulatory approvals for its therapeutics under development and intends to submit its most promising potential therapeutic candidates to the appropriate regulatory body as part of the approval process. The submission of this pre-IND meeting request for collaborative discussions with the FDA has been submitted in anticipation of filing the first of several clinical IND packages.

“This is a significant milestone for PsyBio as there are currently no approved indications for psilocybin or other similar compounds,” stated Michael Spigarelli, MD, PhD, MBA, PsyBio’s Chief Medical. “We look forward to working with the FDA to define what would be considered sufficient proof of safety and efficacy within the target populations. This is the first step to defining an acceptable medical use for these compounds, a critically necessary component in order to facilitate further developing and manufacturing at the necessary scale for this new class of potential therapeutics.”

“This submission firmly establishes PsyBio among the top biotechnology companies actually seeking regulatory approval for their psychoactive therapeutic candidates,” stated Evan Levine, Chief Executive Officer, PsyBio. “The Company’s logical and validated testing approach allows PsyBio to effectively design and develop therapeutics to potentially treat specific clinical conditions and submit those to the appropriate regulatory agencies for approval and marketing authorization.  PsyBio is doing this as part of our commitment to research and develop potential therapeutics for mental and neurological health.”

About PsyBio Therapeutics Corp.

PsyBio is an intellectual property driven biotechnology company developing novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a Bio Medicinal Chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward looking-statements in this press release include statements regarding: the ability of PsyBio to develop novel formulations to potentially treat neurologic and psychologic conditions and other disorders; the ability of PsyBio to launch clinical trials; the ability of PsyBio to build its intellectual property portfolio of novel drug candidates; the ability of PsyBio to move target candidates into scaled commercial manufacturing and regulatory application; the ability to achieve cost competitive synthesis with reduced environmental impact over current production methods; and the ability of PsyBio to move target candidates into scaled commercial manufacturing and regulatory application.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: PsyBio will be successful in protecting its intellectual property; PsyBio will be successful in discovering new valuable target molecules; pre-IND consultation with the FDA will be productive and yield favourable results; PsyBio will file its IND Application within anticipated timeframes; PsyBio will be successful in obtaining IND Applications and will be able to obtain all necessary approvals for clinical trials; PsyBio will be successful in launching clinical trials; the results of preclinical safety and efficacy testing will be favourable; PsyBio’s technology will be safe and effective; a confirmed signal will be identified in PsyBio’s selected indications; and that drug development involves long lead times, is very expensive and involves many variables of uncertainty. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio’s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The FDA other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Posted on

PsyBio Therapeutics Announces Participation in Upcoming Investor Conferences in September 2021

PsyBio Therapeutics Announces Participation in Upcoming Investor Conferences in September 2021

OXFORD, Ohio and COCONUT CREEK, Fla., Sept. 20, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company developing novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that Evan Levine, Chief Executive Officer and Chairman, will participate in the Maxim Group Advances in Mental Health Virtual Conference and the Benzinga Virtual Global Healthcare Small Cap Conference in September 2021.

The Maxim Group Advances in Mental Health Virtual Conference
Wednesday, September 22nd at 3:00 p.m. ET
Delivery, Manufacturing & Technology Panel
Registration: https://m-vest.com/events/advances-in-mental-health

Benzinga Virtual Global Healthcare Small Cap Conference
Thursday, September 30th at 2:20 p.m. ET
Registration: https://www.benzinga.com/events/small-cap/healthcare/

The PsyBio management team will be available for one-on-one meetings for the duration of both conferences. To schedule a meeting or for more information on the conferences, please contact your Maxim or Benzinga representative, or KCSA Strategic Communications by emailing Valter@KCSA.com.

About PsyBio Therapeutics Corp.

PsyBio Therapeutics is an intellectual property driven biotechnology company developing novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a Bio Medicinal Chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward looking-statements in this press release include, amongst other things, statements regarding PsyBio’s participation in the Maxim Group Advances in Mental Health Virtual Conference and the Benzinga Virtual Global Healthcare Small Cap Conference.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: PsyBio will be successful in protecting its intellectual property; PsyBio will be successful in discovering new valuable target molecules; PsyBio will file its initial pre-Investigational New Drug (“IND“) Application request and IND Application within anticipated timeframes; PsyBio will be successful in obtaining IND Applications and will be able to obtain all necessary approvals for clinical trials; PsyBio will be successful in launching clinical trials; the results of preclinical safety and efficacy testing will be favourable; PsyBio’s technology will be safe and effective; a confirmed signal will be identified in PsyBio’s selected indications; and that drug development involves long lead times, is very expensive and involves many variables of uncertainty. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio’s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The United States Food and Drug Administration (“FDA“) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (“TSXV“) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.